Phenotypes Associated with This Genotype

Genotype
MGI:3624037

• Allelic Composition: Tg(INS-MT2A,Tyr)1Pne/0
• Genetic Background: NOD.FVB-Tg(INS-MT2A,Tyr)1Pne

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

homeostasis/metabolism

decreased physiological sensitivity to xenobiotic ( J:108415 )

• treatment of transgenic NOD mice with cyclophosphamide (CYP) accelerated NOD diabetes; 20 days after injection of CYP 93% of transgenic mice are diabetic compared with 7% of treated controls

• transgenic mice on the FVB background do not develop diabetes with the same regimen of CYP treatment as the NOD transgenic mice

• transgenic mice exhibit greater resistance to induced diabetes after treatment with streptozotocin compared with NOD controls

endocrine/exocrine glands

abnormal pancreatic islet morphology ( J:108415 )

• 8 days after CYP treatment significantly more islets of transgenic NOD mice appear small and disrupted compared to treated NOD controls; percentages of damaged areas (Caspase-3 positive) in islets are 11.7 and 5.5% in transgenic NOD and control NOD mice respectively

• cultured islets of transgenic NOD mice are more sensitive to a mix of cytokines (Il-beta, Tnfa and Ifng) than NOD control islets as revealed by Caspase-3 activity

decreased pancreatic beta cell number ( J:108415 )

• beta cell damage is significantly increased in transgenic mice after CYP injection compared to controls; pancreatic insulin content is only 36% of original level after 8 days compared to 76% in control NOD mice

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
type 1 diabetes mellitus		DOID:9744	OMIM:222100	J:108415